Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2351

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

Yin Yuan, Stephen Boyle

Blood (2021) 137 (23): 3310.

https://doi.org/10.1182/blood.2021011357

Published: 2021

Journal Articles

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Chloé Friedrich, Sylvain Barreau

Blood (2020) 136 (1): 148.

https://doi.org/10.1182/blood.2020005728

Published: 2020

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Changes in the Main Bone Marrow Cell Subpopulations May Potentially Contribute to the Initiation of Acute Myeloid Leukemia

Shlomit Yehudai-Reshef, PhD, Rawan Sabah, Tal Gabay, Tsila Zuckerman, MD

Blood (2019) 134 (Supplement_1): 2494.

https://doi.org/10.1182/blood-2019-128097

Published: 2019

Journal Articles

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Meera Yogarajah, MD, Phuong L. Nguyen, MD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Kebede H. Begna, MD, Michelle A Elliott, MD, Naseema Gangat, MBBS, William J Hogan, MB, BCh, Ayalew Tefferi, MD, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2019) 134 (Supplement_1): 5441.

https://doi.org/10.1182/blood-2019-125439

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Jifeng Yu, MD, Yingmei Li, MD, Haizhou Xing, Hui Sun, Dingming Wan, MD, Yanfang Liu, Xinsheng Xie, MD, Chong Wang, Ling Sun, MD PhD, Kai Sun, MD, Zhongxing Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 5207.

https://doi.org/10.1182/blood-2019-127580

Published: 2019

Journal Articles

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Alexander Chan, MD, Yanming Zhang, MD, Sean M. Devlin, PhD, Natasha Lewis, MD, Jeeyeon Baik, Maria E Arcila, MD, Virginia M. Klimek, MD, Mikhail Roshal, MD PhD, Wenbin Xiao, MD PhD

Blood (2019) 134 (Supplement_1): 5439.

https://doi.org/10.1182/blood-2019-122332

Published: 2019

Journal Articles

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Travis Spaulding, MD, Nicholas Strayer, Andrew Sochacki, MD, Shannon Stockton, MD, Alexander Silver, Rodney Dixon Dorand, MD PhD, Siwei Zhang, PhD, Ya-Chen Lin, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 5440.

https://doi.org/10.1182/blood-2019-122400

Published: 2019

Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood (2019) 134 (Supplement_1): 4237.

https://doi.org/10.1182/blood-2019-125974

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Rafee Talukder, MD, Martha P. Mims, MD PhD, Gustavo A. Rivero, MD

Blood (2019) 134 (Supplement_1): 1438.

https://doi.org/10.1182/blood-2019-131581

Published: 2019

Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD

Blood (2019) 134 (Supplement_1): 1420.

https://doi.org/10.1182/blood-2019-127865

Published: 2019

Journal Articles

Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages

Jamie A Moore, BSc, MSc, Jayna J Mistry, BSc, Rebecca H Horton, Charlotte Hellmich, MBBChir, Adam Pattinson, MSc, BSc, Adam Morfakis, BSc, Yu Sun, BSc, MSc, PhD, Matthew Lawes, MD, Christopher J Morris, PhD, Anna Haestier, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD

Blood (2019) 134 (Supplement_1): 1427.

https://doi.org/10.1182/blood-2019-128447

Published: 2019

Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1442.

https://doi.org/10.1182/blood-2019-123845

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Changes in the Main Bone Marrow Cell Subpopulations May Potentially Contribute to the Initiation of Acute Myeloid Leukemia

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only